JCR Pharmaceuticals

Adenovirus
#AAV #Alexion #Drug delivery #Gene therapy #JCR Pharmaceuticals #License agreement

JCR and Alexion deal boosts AAV-based gene therapy

JCR Pharmaceuticals and Alexion, AstraZeneca Rare Disease, have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines.  JUST-AAV encompasses a range of vector types optimised for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy.  Under the terms of the… Read More

#Business & Investment #News